Eli Lilly and Company (LLY) Financials

$861.11 +31.69 (+3.82%)

As of 04/24/2025 03:59 PM Eastern

Annual Income Statements for Eli Lilly and Company

This table shows Eli Lilly and Company's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	2,408	2,738	-204	3,232	8,318	6,194	5,582	6,245	5,240	10,590
Consolidated Net Income / (Loss)	2,408	2,738	-204	3,232	8,318	6,194	5,582	6,245	5,240	10,590
Net Income / (Loss) Continuing Operations	2,408	2,738	-86	3,151	4,638	6,194	5,582	6,245	5,240	10,590
Total Pre-Tax Income	2,790	3,374	2,305	3,680	5,266	7,230	6,156	6,806	6,555	12,680
Total Operating Income	2,689	3,261	2,003	3,535	4,974	6,058	6,357	7,127	6,458	12,899
Total Gross Profit	14,922	15,512	15,526	16,812	17,598	19,057	21,006	21,912	27,042	36,624
Total Revenue	19,959	21,222	19,974	21,493	22,320	24,540	28,318	28,541	34,124	45,043
Operating Revenue	19,959	21,222	19,974	21,493	22,320	24,540	28,318	28,541	34,124	45,043
Total Cost of Revenue	5,037	5,710	4,448	4,682	4,721	5,483	7,313	6,630	7,082	8,418
Operating Cost of Revenue	5,037	5,710	4,448	4,682	4,721	5,483	7,313	6,630	7,082	8,418
Total Operating Expenses	12,232	12,251	13,523	13,277	12,624	12,999	14,649	14,784	20,584	23,725
Selling, General & Admin Expense	6,533	6,528	5,982	5,975	6,214	6,121	6,432	6,440	7,403	8,594
Research & Development Expense	5,331	5,340	6,209	7,035	5,835	6,746	7,901	8,099	13,113	14,271
Restructuring Charge	368	383	1,332	267	576	131	316	245	68	861
Total Other Income / (Expense), net	101	113	302	146	292	1,172	-202	-321	97	-219
Other Income / (Expense), net	101	113	302	146	292	1,172	-202	-321	97	-219
Income Tax Expense	382	636	2,391	530	628	1,036	574	562	1,314	2,090
Basic Earnings per Share	$2.27	$2.59	($0.19)	$3.14	$8.93	$6.82	$6.15	$6.93	$5.82	$11.76
Weighted Average Basic Shares Outstanding	1.06B	1.06B	1.05B	1.03B	931.06M	907.63M	906.96M	901.74M	900.18M	900.61M
Diluted Earnings per Share	$2.26	$2.58	($0.19)	$3.13	$8.89	$6.79	$6.12	$6.90	$5.80	$11.71
Weighted Average Diluted Shares Outstanding	1.07B	1.06B	1.05B	1.03B	935.68M	912.51M	911.68M	904.62M	903.28M	904.06M
Weighted Average Basic & Diluted Shares Outstanding	1.06B	1.06B	1.07B	1.03B	956.38M	958.43M	952.35M	950.30M	950.16M	948.17M
Cash Dividends to Common per Share	$2.00	$2.05	$2.12	$2.25	$2.58	$3.07	$3.53	$4.07	$4.69	$5.40

This table shows Eli Lilly and Company's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	953	1,452	1,938	1,345	1,763	-57	2,190	2,243	2,967	970	4,410
Consolidated Net Income / (Loss)	953	1,452	1,938	1,345	1,763	-57	2,190	2,243	2,967	970	4,410
Net Income / (Loss) Continuing Operations	953	1,452	1,938	1,345	1,763	-57	2,190	2,243	2,967	970	4,410
Total Pre-Tax Income	1,091	1,566	2,096	1,530	2,089	427	2,509	2,536	3,517	1,588	5,039
Total Operating Income	1,210	1,677	1,836	1,494	2,126	450	2,388	2,509	3,715	1,526	5,149
Total Gross Profit	5,058	5,363	5,754	5,333	6,505	7,639	7,565	7,095	9,133	9,268	11,129
Total Revenue	6,488	6,942	7,302	6,960	8,312	9,499	9,353	8,768	11,303	11,439	13,533
Operating Revenue	6,488	6,942	7,302	6,960	8,312	9,499	9,353	8,768	11,303	11,439	13,533
Total Cost of Revenue	1,431	1,579	1,548	1,627	1,807	1,860	1,788	1,674	2,170	2,171	2,404
Operating Cost of Revenue	1,431	1,579	1,548	1,627	1,807	1,860	1,788	1,674	2,170	2,171	2,404
Total Operating Expenses	3,847	3,686	3,917	3,839	4,379	7,188	5,178	4,586	5,418	7,742	5,980
Selling, General & Admin Expense	1,625	1,614	1,643	1,749	1,925	1,804	1,925	1,952	2,117	2,100	2,425
Research & Development Expense	2,222	1,865	2,236	2,090	2,454	5,384	3,185	2,633	2,866	5,561	3,212
Total Other Income / (Expense), net	-119	-111	260	36	-37	-23	121	27	-198	62	-110
Other Income / (Expense), net	-119	-111	260	36	-37	-23	121	27	-198	62	-110
Income Tax Expense	138	114	159	185	326	485	319	293	550	618	629
Basic Earnings per Share	$1.06	$1.61	$2.15	$1.49	$1.96	($0.06)	$2.43	$2.49	$3.29	$1.08	$4.90
Weighted Average Basic Shares Outstanding	900.30M	900.70M	901.74M	901M	899.70M	899.80M	900.18M	900.80M	900.90M	901M	900.61M
Diluted Earnings per Share	$1.05	$1.61	$2.14	$1.49	$1.95	($0.06)	$2.42	$2.48	$3.28	$1.07	$4.88
Weighted Average Diluted Shares Outstanding	902.90M	903.80M	904.62M	903.30M	902.70M	899.80M	903.28M	903.80M	904.20M	905M	904.06M
Weighted Average Basic & Diluted Shares Outstanding	950.17M	950.18M	950.30M	949.27M	949.30M	949.31M	950.16M	950.41M	950.43M	949.32M	948.17M

This table details how cash moves in and out of Eli Lilly and Company's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-205	916	1,954	1,526	-5,661	1,320	161	-1,752	752	450
Net Cash From Operating Activities	2,965	4,851	5,616	5,525	4,837	6,500	7,366	7,586	4,240	8,818
Net Cash From Continuing Operating Activities	2,965	4,851	5,616	5,525	4,837	6,500	7,366	7,586	4,240	8,818
Net Income / (Loss) Continuing Operations	2,408	2,738	-204	3,232	8,318	6,194	5,582	6,245	5,240	10,590
Consolidated Net Income / (Loss)	2,408	2,738	-204	3,232	8,318	6,194	5,582	6,245	5,240	10,590
Depreciation Expense	1,428	1,497	1,567	1,609	1,233	1,324	1,548	1,523	1,527	1,767
Non-Cash Adjustments To Reconcile Net Income	753	285	1,394	2,236	-3,589	-470	1,324	1,543	2,573	3,752
Changes in Operating Assets and Liabilities, net	-1,624	332	2,859	-1,553	-1,126	-548	-1,088	-1,725	-5,101	-7,291
Net Cash From Investing Activities	27	-3,139	-3,784	1,906	-8,083	-2,259	-2,868	-3,763	-7,153	-9,302
Net Cash From Continuing Investing Activities	27	-3,139	-3,784	1,906	-8,083	-2,259	-2,868	-3,763	-7,153	-9,302
Purchase of Property, Plant & Equipment	-1,066	-1,037	-1,077	-1,211	-1,034	-1,388	-1,310	-1,854	-3,448	-5,058
Acquisitions	-5,843	-100	-1,969	-1,808	-7,611	-1,491	-1,416	-1,458	-4,989	-4,294
Purchase of Investments	-4,069	-5,673	-8,001	-950	-290	-370	-1,013	-708	-829	-776
Divestitures	-	-	0.00	0.00	355	-	216	96	1,604	601
Sale and/or Maturity of Investments	5,230	3,728	7,439	6,062	746	887	847	464	700	523
Other Investing Activities, net	5,272	-130	-175	-188	-249	103	-192	-302	-192	-298
Net Cash From Financing Activities	-3,111	-560	143	-5,905	-2,325	-3,137	-4,131	-5,407	3,496	1,230
Net Cash From Continuing Financing Activities	-3,111	-560	143	-5,905	-2,325	-3,137	-4,131	-5,407	3,496	1,230
Repayment of Debt	-4,689	992	-995	-3,580	-2,071	-2,012	-2,201	-371	4,356	-3,007
Repurchase of Common Equity	-750	-600	-300	-4,151	-4,400	-500	-1,250	-1,500	-750	-2,500
Payment of Dividends	-2,127	-2,159	-2,192	-2,312	-2,410	-2,687	-3,087	-3,536	-4,069	-4,680
Issuance of Debt	4,455	1,207	3,630	2,478	6,556	2,062	2,407	0.00	3,959	11,417
Effect of Exchange Rate Changes	-86	-236	-21	-	-90	216	-	-168	169	-297

This table details how cash moves in and out of Eli Lilly and Company's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	164	-5.50	-550	1,479	-851	-314	438	-358	763	145	-101
Net Cash From Operating Activities	1,183	2,217	1,663	1,731	632	2,190	-312	1,166	1,466	3,712	2,474
Net Cash From Continuing Operating Activities	1,183	2,217	1,663	1,731	632	2,190	-312	1,166	1,466	3,712	2,474
Net Income / (Loss) Continuing Operations	953	1,452	1,938	1,345	1,763	-57	2,190	2,243	2,967	970	4,410
Consolidated Net Income / (Loss)	953	1,452	1,938	1,345	1,763	-57	2,190	2,243	2,967	970	4,410
Depreciation Expense	349	363	375	362	366	411	388	401	414	467	485
Non-Cash Adjustments To Reconcile Net Income	652	184	15	250	324	1,401	597	254	523	2,747	228
Changes in Operating Assets and Liabilities, net	-770	218	-665	-227	-1,822	435	-3,486	-1,732	-2,439	-472	-2,649
Net Cash From Investing Activities	-827	-955	-944	-689	-459	-3,081	-2,924	-1,178	-2,199	-4,005	-1,921
Net Cash From Continuing Investing Activities	-827	-955	-944	-689	-459	-3,081	-2,924	-1,178	-2,199	-4,005	-1,921
Purchase of Property, Plant & Equipment	-371	-617	-501	-669	-738	-970	-1,071	-986	-1,225	-1,351	-1,496
Acquisitions	-443	-35	-465	-235	-98	-3,031	-1,625	-97	-1,126	-2,820	-251
Purchase of Investments	-153	-255	-169	-169	-234	-151	-275	-142	-157	-295	-182
Divestitures	-	-	30	-	-	-	-	-	-	-	70
Sale and/or Maturity of Investments	118	109	129	343	155	133	69	112	214	100	97
Other Investing Activities, net	22	-223	32	40	457	-666	-23	-65	96	-170	-159
Net Cash From Financing Activities	-124	-1,263	-1,141	412	-1,033	572	3,545	-311	1,556	211	-225
Net Cash From Continuing Financing Activities	-124	-1,263	-1,141	412	-1,033	572	3,545	-311	1,556	211	-225
Repayment of Debt	760	-381	-257	-1,779	-16	1,588	4,563	-5,595	2,728	-3,137	2,997
Repurchase of Common Equity	-	-	-	-750	-	-	-	0.00	-	-446	-2,054
Payment of Dividends	-884	-882	-884	-1,017	-1,018	-1,016	-1,018	-1,169	-1,172	-1,171	-1,168
Effect of Exchange Rate Changes	-69	-3.60	-128	25	9.20	5.30	129	-36	-60	227	-429

This table presents Eli Lilly and Company's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	35,569	38,806	44,981	43,908	39,286	46,633	48,806	49,490	64,006	78,715
Total Current Assets	12,574	15,101	19,202	20,550	13,710	17,462	18,452	18,035	25,727	32,740
Cash & Equivalents	3,666	4,582	6,536	7,321	2,338	3,657	3,819	2,067	2,819	3,268
Short-Term Investments	785	1,457	1,498	88	101	24	90	145	109	155
Accounts Receivable	4,072	4,766	5,262	5,777	5,542	6,929	8,127	8,559	11,336	13,275
Inventories, net	3,446	3,562	4,458	3,098	3,191	3,980	3,886	4,310	5,773	7,589
Prepaid Expenses	604	735	1,448	2,037	2,539	2,872	2,531	2,947	5,541	8,341
Other Current Assets	-	-	-	-	-	-	-	7.30	150	111
Plant, Property, & Equipment, net	8,054	8,253	8,827	7,996	7,873	8,682	8,985	10,144	12,914	17,102
Total Noncurrent Assets	14,942	15,452	16,952	15,363	17,704	20,489	21,369	21,311	25,366	28,873
Long-Term Investments	3,647	5,208	5,679	2,005	1,962	2,967	3,213	2,902	3,052	3,216
Goodwill	4,040	3,973	4,370	1,367	3,679	3,767	3,892	4,073	4,940	5,770
Intangible Assets	5,035	4,358	4,029	1,068	6,618	7,450	7,692	7,207	6,907	6,166
Noncurrent Deferred & Refundable Income Taxes	-	-	1,166	2,614	2,573	2,830	2,489	2,793	5,477	8,001
Other Noncurrent Operating Assets	2,221	1,914	1,708	1,825	2,871	3,475	4,083	4,337	4,990	5,720
Total Liabilities & Shareholders' Equity	35,569	38,806	44,981	43,908	39,286	46,633	48,806	49,490	64,006	78,715
Total Liabilities	20,979	24,725	33,313	32,999	36,587	40,808	39,651	38,714	53,143	64,443
Total Current Liabilities	8,230	10,987	14,536	11,888	11,775	12,482	15,053	17,138	27,293	28,377
Short-Term Debt	6.10	1,937	3,707	1,102	1,499	8.70	1,538	1,501	6,905	5,117
Accounts Payable	1,338	1,349	1,411	1,207	1,405	1,607	1,671	1,931	2,599	3,229
Dividends Payable	539	548	591	651	672	771	886	1,017	1,169	1,346
Current Employee Benefit Liabilities	967	897	998	956	916	997	958	1,060	1,650	2,094
Other Current Liabilities	5,020	6,136	7,297	6,886	7,123	8,603	9,873	11,630	14,970	16,591
Total Noncurrent Liabilities	12,749	13,739	18,777	21,111	24,812	28,326	24,599	21,576	25,849	36,067
Long-Term Debt	7,972	8,368	9,941	9,196	13,818	16,587	15,346	14,738	18,321	28,527
Noncurrent Deferred Revenue	869	689	3,777	3,700	3,607	3,838	3,920	3,710	3,849	4,061
Noncurrent Employee Benefit Liabilities	2,160	2,454	3,514	2,802	3,698	4,095	1,954	1,305	1,439	1,301
Other Noncurrent Operating Liabilities	1,747	2,228	1,546	1,358	1,501	1,708	1,644	1,824	2,241	2,178
Commitments & Contingencies	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	14,590	14,081	11,668	10,909	2,699	5,825	9,155	10,775	10,864	14,272
Total Preferred & Common Equity	14,571	14,008	11,592	9,829	2,607	5,642	8,979	10,650	10,772	14,192
Total Common Equity	14,571	14,008	11,592	9,832	2,607	5,642	8,979	10,650	10,772	14,192
Common Stock	6,243	6,329	6,506	7,245	7,284	7,377	7,430	7,516	7,844	8,032
Retained Earnings	16,012	16,046	13,894	11,396	4,920	7,830	8,959	10,043	10,312	13,545
Treasury Stock	-90	-81	-76	-69	-61	-56	-53	-51	-44	-50
Accumulated Other Comprehensive Income / (Loss)	-4,581	-5,274	-5,719	-5,729	-6,524	-6,496	-4,343	-3,845	-4,327	-4,322
Other Equity Adjustments	-3,013	-3,013	-3,013	-3,010	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013
Noncontrolling Interest	19	73	76	1,080	92	184	176	126	92	80

This table presents Eli Lilly and Company's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Total Assets	47,064	47,462	49,490	53,163	54,814	57,916	64,006	63,944	71,875	75,607	78,715
Total Current Assets	17,115	17,640	18,035	20,811	21,332	23,007	25,727	25,189	30,204	31,415	32,740
Cash & Equivalents	2,623	2,617	2,067	3,546	2,695	2,381	2,819	2,460	3,224	3,369	3,268
Short-Term Investments	114	125	145	123	135	113	109	126	140	149	155
Accounts Receivable	7,672	8,325	8,559	9,022	9,171	10,364	11,336	10,014	13,079	12,052	13,275
Inventories, net	3,899	3,831	4,310	4,545	4,799	4,901	5,773	6,102	6,482	7,460	7,589
Prepaid Expenses	2,807	2,742	2,947	3,575	4,532	5,248	5,541	6,349	7,138	8,251	8,341
Other Current Assets	-	-	7.30	-	-	-	150	139	142	135	111
Plant, Property, & Equipment, net	9,128	9,311	10,144	10,546	11,277	11,863	12,914	13,624	14,829	16,172	17,102
Total Noncurrent Assets	20,820	20,510	21,311	21,805	22,205	23,045	25,366	25,131	26,841	28,020	28,873
Long-Term Investments	2,587	2,575	2,902	2,750	2,745	2,692	3,052	3,087	2,878	3,200	3,216
Goodwill	3,892	3,892	4,073	4,073	4,079	4,085	4,940	4,940	5,768	5,768	5,770
Intangible Assets	7,498	7,124	7,207	7,087	6,904	6,782	6,907	6,762	6,636	6,537	6,166
Noncurrent Deferred & Refundable Income Taxes	2,372	2,384	2,793	3,407	3,806	4,575	5,477	5,634	6,655	7,392	8,001
Other Noncurrent Operating Assets	4,472	4,536	4,337	4,488	4,672	4,912	4,990	4,708	4,904	5,122	5,720
Total Liabilities & Shareholders' Equity	47,064	47,462	49,490	53,163	54,814	57,916	64,006	63,944	71,875	75,607	78,715
Total Liabilities	38,404	37,296	38,714	41,868	43,665	46,608	53,143	51,046	58,239	61,286	64,443
Total Current Liabilities	15,621	15,653	17,138	16,010	18,915	21,998	27,293	18,598	27,121	24,674	28,377
Short-Term Debt	2,122	1,745	1,501	3.10	662	2,245	6,905	1,652	5,162	2,074	5,117
Accounts Payable	1,659	1,683	1,931	2,016	2,474	2,435	2,599	2,474	2,925	2,887	3,229
Dividends Payable	882	0.00	1,017	0.00	1,016	0.00	1,169	0.00	1,171	0.00	1,346
Current Employee Benefit Liabilities	836	984	1,060	740	868	1,233	1,650	844	1,168	1,703	2,094
Other Current Liabilities	9,995	10,555	11,630	11,723	12,662	14,108	14,970	13,629	16,696	18,010	16,591
Total Noncurrent Liabilities	22,784	21,643	21,576	25,858	24,750	24,610	25,849	32,448	31,118	36,612	36,067
Long-Term Debt	14,692	14,144	14,738	18,881	18,158	17,924	18,321	24,560	23,730	29,045	28,527
Noncurrent Deferred Revenue	3,558	3,642	3,710	3,842	3,331	3,468	3,849	4,189	3,497	3,879	4,061
Noncurrent Employee Benefit Liabilities	1,889	1,833	1,305	1,313	1,309	1,312	1,439	1,428	1,420	1,449	1,301
Other Noncurrent Operating Liabilities	1,783	1,853	1,824	1,823	1,952	1,906	2,241	2,271	2,471	2,239	2,178
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	8,659	10,166	10,775	11,295	11,149	11,307	10,864	12,897	13,636	14,321	14,272
Total Preferred & Common Equity	8,545	10,070	10,650	11,190	11,064	11,220	10,772	12,812	13,562	14,240	14,192
Total Common Equity	8,545	10,070	10,650	11,190	11,064	11,220	10,772	12,812	13,562	14,240	14,192
Common Stock	7,340	7,423	7,516	7,387	7,542	7,754	7,844	7,604	7,808	7,934	8,032
Retained Earnings	8,556	10,007	10,043	10,639	10,369	10,310	10,312	12,554	13,178	13,627	13,545
Treasury Stock	-51	-51	-51	-45	-45	-45	-44	-33	-33	-33	-50
Accumulated Other Comprehensive Income / (Loss)	-4,288	-4,296	-3,845	-3,777	-3,789	-3,785	-4,327	-4,300	-4,379	-4,275	-4,322
Other Equity Adjustments	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013
Noncontrolling Interest	115	96	126	105	86	87	92	85	74	81	80

This table displays calculated financial ratios and metrics derived from Eli Lilly and Company's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.75%	6.33%	-5.88%	7.61%	3.84%	9.95%	15.40%	0.79%	19.56%	32.00%
EBITDA Growth	-3.69%	15.48%	-20.50%	36.60%	22.87%	31.63%	-9.95%	8.12%	-2.97%	78.76%
EBIT Growth	-7.01%	20.93%	-31.69%	59.67%	43.09%	37.30%	-14.86%	10.57%	-3.70%	93.46%
NOPAT Growth	9.55%	13.98%	-102.84%	4,129.35%	44.78%	18.46%	11.07%	13.44%	-21.04%	108.65%
Net Income Growth	0.75%	13.67%	-107.46%	1,683.54%	157.38%	-25.54%	-9.88%	11.88%	-16.08%	102.08%
EPS Growth	1.35%	14.16%	-107.36%	1,747.37%	184.03%	-23.62%	-9.87%	12.75%	-15.94%	101.90%
Operating Cash Flow Growth	-33.51%	63.63%	15.76%	-1.62%	-12.45%	34.38%	13.33%	2.98%	-44.10%	107.96%
Free Cash Flow Firm Growth	-206.41%	211.79%	-64.21%	467.12%	-134.02%	207.08%	-14.66%	36.81%	-193.35%	82.11%
Invested Capital Growth	64.25%	-8.81%	-10.92%	-41.23%	99.37%	15.79%	19.71%	15.72%	36.48%	36.27%
Revenue Q/Q Growth	1.29%	1.85%	-11.11%	12.42%	2.18%	5.71%	2.02%	-2.39%	6.40%	10.23%
EBITDA Q/Q Growth	-1.52%	10.14%	-10.06%	9.73%	12.68%	10.79%	-6.68%	2.28%	5.55%	22.23%
EBIT Q/Q Growth	-2.41%	15.29%	-17.84%	17.03%	16.25%	12.55%	-9.27%	3.92%	6.71%	24.92%
NOPAT Q/Q Growth	5.56%	6.23%	-103.94%	564.66%	4.24%	9.45%	1.81%	-1.51%	7.63%	28.86%
Net Income Q/Q Growth	2.12%	12.00%	-109.17%	610.95%	4.72%	11.15%	-6.54%	3.51%	5.05%	26.52%
EPS Q/Q Growth	2.26%	12.17%	-109.00%	580.43%	8.15%	8.64%	-6.56%	3.92%	5.07%	26.59%
Operating Cash Flow Q/Q Growth	-13.05%	26.31%	-4.47%	-5.07%	11.92%	-2.23%	6.45%	-7.32%	-31.77%	46.18%
Free Cash Flow Firm Q/Q Growth	-118.20%	136.36%	-37.81%	281,157.01%	-163.80%	-36.56%	-30.64%	-9.03%	-323.23%	85.95%
Invested Capital Q/Q Growth	0.74%	-12.88%	-20.48%	-54.60%	-8.97%	4.63%	10.86%	10.51%	18.97%	10.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	74.76%	73.09%	77.73%	78.22%	78.85%	77.66%	74.18%	76.77%	79.25%	81.31%
EBITDA Margin	21.13%	22.95%	19.39%	24.61%	29.12%	34.86%	27.20%	29.18%	23.68%	32.07%
Operating Margin	13.47%	15.37%	10.03%	16.44%	22.29%	24.69%	22.45%	24.97%	18.92%	28.64%
EBIT Margin	13.98%	15.90%	11.54%	17.12%	23.59%	29.46%	21.74%	23.85%	19.21%	28.15%
Profit (Net Income) Margin	12.07%	12.90%	-1.02%	15.04%	37.27%	25.24%	19.71%	21.88%	15.36%	23.51%
Tax Burden Percent	86.32%	81.14%	-8.86%	87.82%	157.97%	85.67%	90.68%	91.75%	79.95%	83.51%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	13.68%	18.86%	103.75%	14.39%	11.93%	14.33%	9.32%	8.25%	20.05%	16.49%
Return on Invested Capital (ROIC)	19.23%	18.44%	-0.58%	31.26%	40.84%	33.67%	31.72%	30.61%	19.05%	29.15%
ROIC Less NNEP Spread (ROIC-NNEP)	16.25%	714.44%	-196.04%	18.46%	141.22%	42.67%	30.01%	28.03%	19.53%	28.41%
Return on Net Nonoperating Assets (RNNOA)	-3.16%	0.66%	-1.01%	-2.63%	81.41%	111.65%	42.80%	32.05%	29.38%	55.11%
Return on Equity (ROE)	16.07%	19.10%	-1.59%	28.63%	122.26%	145.32%	74.52%	62.67%	48.43%	84.26%
Cash Return on Invested Capital (CROIC)	-29.40%	27.65%	10.97%	83.19%	-25.54%	19.03%	13.78%	16.04%	-11.80%	-1.55%
Operating Return on Assets (OROA)	7.76%	9.07%	5.50%	8.28%	12.66%	16.83%	12.90%	13.85%	11.55%	17.77%
Return on Assets (ROA)	6.70%	7.36%	-0.49%	7.27%	20.00%	14.42%	11.70%	12.71%	9.23%	14.84%
Return on Common Equity (ROCE)	16.05%	19.04%	-1.58%	27.17%	111.75%	140.62%	72.74%	61.72%	47.95%	83.69%
Return on Equity Simple (ROE_SIMPLE)	16.53%	19.54%	-1.76%	32.88%	319.09%	109.79%	62.16%	58.64%	48.65%	74.62%
Net Operating Profit after Tax (NOPAT)	2,322	2,646	-75	3,026	4,381	5,190	5,765	6,539	5,163	10,773
NOPAT Margin	11.63%	12.47%	-0.38%	14.08%	19.63%	21.15%	20.36%	22.91%	15.13%	23.92%
Net Nonoperating Expense Percent (NNEP)	2.98%	-696.00%	195.46%	12.81%	-100.38%	-9.00%	1.71%	2.58%	-0.47%	0.75%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	24.21%	14.31%	22.48%
Cost of Revenue to Revenue	25.24%	26.91%	22.27%	21.78%	21.15%	22.34%	25.82%	23.23%	20.75%	18.69%
SG&A Expenses to Revenue	32.73%	30.76%	29.95%	27.80%	27.84%	24.94%	22.71%	22.57%	21.69%	19.08%
R&D to Revenue	26.71%	25.16%	31.08%	32.73%	26.14%	27.49%	27.90%	28.38%	38.43%	31.68%
Operating Expenses to Revenue	61.29%	57.73%	67.70%	61.77%	56.56%	52.97%	51.73%	51.80%	60.32%	52.67%
Earnings before Interest and Taxes (EBIT)	2,790	3,374	2,305	3,680	5,266	7,230	6,156	6,806	6,555	12,680
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4,218	4,871	3,872	5,289	6,499	8,554	7,703	8,329	8,082	14,447
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.24	4.87	6.86	11.17	44.29	26.15	27.26	30.52	48.48	49.09
Price to Tangible Book Value (P/TBV)	13.89	12.01	24.92	14.85	0.00	0.00	0.00	0.00	0.00	308.90
Price to Revenue (P/Rev)	3.82	3.21	3.98	5.11	5.17	6.01	8.65	11.39	15.30	15.47
Price to Earnings (P/E)	31.69	24.90	0.00	33.98	13.88	23.82	43.86	52.05	99.65	65.79
Dividend Yield	2.79%	3.18%	2.75%	2.12%	2.09%	1.83%	1.27%	1.09%	0.78%	0.67%
Earnings Yield	3.16%	4.02%	0.00%	2.94%	7.21%	4.20%	2.28%	1.92%	1.00%	1.52%
Enterprise Value to Invested Capital (EV/IC)	5.08	4.92	6.53	15.60	8.85	9.53	12.86	14.67	17.31	16.98
Enterprise Value to Revenue (EV/Rev)	3.82	3.17	3.98	5.20	5.67	6.43	9.00	11.78	15.87	16.07
Enterprise Value to EBITDA (EV/EBITDA)	18.07	13.82	20.55	21.13	19.46	18.43	33.07	40.37	67.01	50.10
Enterprise Value to EBIT (EV/EBIT)	27.32	19.95	34.53	30.37	24.02	21.81	41.39	49.41	82.62	57.08
Enterprise Value to NOPAT (EV/NOPAT)	32.83	25.43	0.00	36.94	28.87	30.38	44.19	51.42	104.89	67.19
Enterprise Value to Operating Cash Flow (EV/OCF)	25.71	13.87	14.17	20.23	26.15	24.26	34.59	44.33	127.72	82.09
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	16.96	56.05	13.88	0.00	53.75	101.75	98.17	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.55	0.73	1.17	0.94	5.67	2.85	1.84	1.51	2.32	2.36
Long-Term Debt to Equity	0.55	0.59	0.85	0.84	5.12	2.85	1.68	1.37	1.69	2.00
Financial Leverage	-0.19	0.00	0.01	-0.14	0.58	2.62	1.43	1.14	1.50	1.94
Leverage Ratio	2.40	2.59	3.25	3.94	6.11	10.08	6.37	4.93	5.25	5.68
Compound Leverage Factor	2.40	2.59	3.25	3.94	6.11	10.08	6.37	4.93	5.25	5.68
Debt to Total Capital	35.35%	42.26%	53.91%	48.56%	85.02%	74.02%	64.84%	60.11%	69.90%	70.22%
Short-Term Debt to Total Capital	0.03%	7.94%	14.64%	5.20%	8.32%	0.04%	5.91%	5.56%	19.13%	10.68%
Long-Term Debt to Total Capital	35.32%	34.31%	39.27%	43.36%	76.70%	73.98%	58.94%	54.56%	50.77%	59.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.08%	0.30%	0.30%	5.09%	0.51%	0.82%	0.67%	0.46%	0.25%	0.17%
Common Equity to Total Capital	64.56%	57.44%	45.79%	46.36%	14.47%	25.16%	34.48%	39.42%	29.85%	29.62%
Debt to EBITDA	1.89	2.12	3.52	1.95	2.36	1.94	2.19	1.95	3.12	2.33
Net Debt to EBITDA	-0.03	-0.19	-0.02	0.17	1.68	1.16	1.27	1.34	2.38	1.87
Long-Term Debt to EBITDA	1.89	1.72	2.57	1.74	2.13	1.94	1.99	1.77	2.27	1.97
Debt to NOPAT	3.44	3.89	-181.72	3.40	3.50	3.20	2.93	2.48	4.89	3.12
Net Debt to NOPAT	-0.05	-0.36	0.88	0.29	2.49	1.92	1.69	1.70	3.73	2.51
Long-Term Debt to NOPAT	3.43	3.16	-132.37	3.04	3.15	3.20	2.66	2.25	3.55	2.65
Altman Z-Score	3.78	3.19	2.60	3.36	3.14	3.57	5.04	6.37	6.96	7.90
Noncontrolling Interest Sharing Ratio	0.11%	0.32%	0.58%	5.11%	8.59%	3.24%	2.40%	1.51%	1.00%	0.68%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.53	1.37	1.32	1.73	1.16	1.40	1.23	1.05	0.94	1.15
Quick Ratio	1.04	0.98	0.91	1.11	0.68	0.85	0.80	0.63	0.52	0.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3,549	3,968	1,420	8,053	-2,740	2,934	2,504	3,425	-3,198	-572
Operating Cash Flow to CapEx	526.01%	503.42%	521.51%	456.34%	467.80%	468.30%	562.37%	409.09%	122.99%	174.34%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.56	0.57	0.48	0.48	0.54	0.57	0.59	0.58	0.60	0.63
Accounts Receivable Turnover	5.07	4.80	3.98	3.89	3.94	3.94	3.76	3.42	3.43	3.66
Inventory Turnover	1.63	1.63	1.11	1.24	1.50	1.53	1.86	1.62	1.40	1.26
Fixed Asset Turnover	2.49	2.60	2.34	2.56	2.81	2.96	3.21	2.98	2.96	3.00
Accounts Payable Turnover	4.08	4.25	3.22	3.58	3.61	3.64	4.46	3.68	3.13	2.89
Days Sales Outstanding (DSO)	71.99	76.00	91.63	93.73	92.55	92.74	97.03	106.69	106.40	99.72
Days Inventory Outstanding (DIO)	224.11	223.97	329.09	294.56	243.10	238.67	196.31	225.60	259.81	289.67
Days Payable Outstanding (DPO)	89.36	85.89	113.25	102.05	100.98	100.25	81.79	99.13	116.72	126.33
Cash Conversion Cycle (CCC)	206.75	214.08	307.47	286.25	234.66	231.17	211.56	233.17	249.50	263.06
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	15,009	13,688	12,193	7,166	14,287	16,543	19,804	22,918	31,278	42,623
Invested Capital Turnover	1.65	1.48	1.54	2.22	2.08	1.59	1.56	1.34	1.26	1.22
Increase / (Decrease) in Invested Capital	5,871	-1,322	-1,495	-5,027	7,121	2,256	3,261	3,114	8,361	11,345
Enterprise Value (EV)	76,226	67,295	79,588	111,783	126,461	157,672	254,751	336,279	541,565	723,817
Market Capitalization	76,327	68,163	79,578	109,818	115,453	147,541	244,812	325,028	522,228	696,733
Book Value per Share	$13.15	$12.69	$10.53	$9.28	$2.72	$5.90	$9.39	$11.21	$11.35	$14.95
Tangible Book Value per Share	$4.96	$5.14	$2.90	$6.98	($8.01)	($5.83)	($2.72)	($0.66)	($1.13)	$2.38
Total Capital	22,569	24,386	25,315	21,208	18,016	22,421	26,040	27,014	36,089	47,916
Total Debt	7,979	10,305	13,647	10,299	15,317	16,595	16,885	16,239	25,225	33,644
Total Long-Term Debt	7,972	8,368	9,941	9,196	13,818	16,587	15,346	14,738	18,321	28,527
Net Debt	-120	-941	-66	884	10,916	9,947	9,764	11,125	19,245	27,005
Capital Expenditures (CapEx)	564	964	1,077	1,211	1,034	1,388	1,310	1,854	3,448	5,058
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-102	14	339	2,355	995	1,308	1,029	186	2,411	6,057
Debt-free Net Working Capital (DFNWC)	4,350	6,052	8,373	9,764	3,434	4,989	4,938	2,397	5,338	9,480
Net Working Capital (NWC)	4,344	4,115	4,666	8,662	1,934	4,981	3,400	896	-1,566	4,363
Net Nonoperating Expense (NNE)	-87	-92	129	-206	-3,937	-1,004	183	294	-77	183
Net Nonoperating Obligations (NNO)	419	-393	525	-3,743	11,588	10,718	10,649	12,142	20,415	28,351
Total Depreciation and Amortization (D&A)	1,428	1,497	1,567	1,609	1,233	1,324	1,548	1,523	1,527	1,767
Debt-free, Cash-free Net Working Capital to Revenue	-0.51%	0.06%	1.70%	10.96%	4.46%	5.33%	3.64%	0.65%	7.06%	13.45%
Debt-free Net Working Capital to Revenue	21.80%	28.52%	41.92%	45.43%	15.38%	20.33%	17.44%	8.40%	15.64%	21.05%
Net Working Capital to Revenue	21.76%	19.39%	23.36%	40.30%	8.67%	20.30%	12.01%	3.14%	-4.59%	9.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$8.93	$6.82	$6.15	$6.93	$5.82	$11.76
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	0.00	931.06M	907.63M	906.96M	901.74M	900.18M	900.61M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$8.89	$6.79	$6.12	$6.90	$5.80	$11.71
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	0.00	935.68M	912.51M	911.68M	904.62M	903.28M	904.06M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	0.00	956.38M	958.43M	952.35M	950.30M	950.16M	948.17M
Normalized Net Operating Profit after Tax (NOPAT)	2,639	2,956	2,334	3,254	4,888	5,302	6,051	6,764	5,217	11,491
Normalized NOPAT Margin	13.22%	13.93%	11.69%	15.14%	21.90%	21.61%	21.37%	23.70%	15.29%	25.51%
Pre Tax Income Margin	13.98%	15.90%	11.54%	17.12%	23.59%	29.46%	21.74%	23.85%	19.21%	28.15%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	88.33%	78.85%	-1,074.03%	71.53%	28.97%	43.38%	55.30%	56.62%	77.65%	44.20%
Augmented Payout Ratio	119.45%	100.77%	-1,220.92%	199.95%	81.86%	51.46%	77.70%	80.64%	91.96%	67.80%

This table displays calculated financial ratios and metrics derived from Eli Lilly and Company's official financial filings.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.74%	2.49%	-8.73%	-10.88%	28.12%	36.84%	28.10%	25.98%	35.98%	20.43%	44.68%
EBITDA Growth	-26.66%	18.48%	8.13%	-23.99%	70.52%	-56.53%	17.20%	55.22%	60.13%	145.19%	90.70%
EBIT Growth	-31.56%	25.71%	13.94%	-25.51%	91.48%	-72.71%	19.67%	65.79%	68.38%	271.82%	100.84%
NOPAT Growth	-13.68%	-7.29%	-5.63%	-41.04%	69.82%	-103.89%	22.78%	68.93%	74.65%	1,640.76%	116.22%
Net Income Growth	-31.48%	30.77%	12.26%	-29.32%	85.11%	-103.95%	13.01%	66.77%	68.27%	1,790.42%	101.39%
EPS Growth	-31.37%	31.97%	13.83%	-29.05%	85.71%	-103.73%	13.08%	66.44%	68.21%	1,883.33%	101.65%
Operating Cash Flow Growth	-33.35%	35.89%	-26.48%	-31.41%	-46.60%	-1.23%	-118.76%	-32.62%	132.03%	69.53%	893.14%
Free Cash Flow Firm Growth	-1,498.71%	-251.68%	3.13%	-24.01%	6.70%	-325.46%	-343.13%	-321.33%	-244.64%	-104.87%	-8.95%
Invested Capital Growth	22.25%	16.09%	15.72%	14.91%	20.83%	26.78%	36.48%	40.73%	47.40%	47.29%	36.27%
Revenue Q/Q Growth	-16.93%	6.99%	5.19%	-4.68%	19.43%	14.27%	-1.53%	-6.26%	28.91%	1.21%	18.30%
EBITDA Q/Q Growth	-42.16%	33.94%	28.16%	-23.44%	29.77%	-65.86%	245.56%	1.39%	33.88%	-47.73%	168.76%
EBIT Q/Q Growth	-46.88%	43.51%	33.91%	-27.03%	36.56%	-79.55%	487.27%	1.09%	38.69%	-54.84%	217.22%
NOPAT Q/Q Growth	-52.57%	47.14%	9.18%	-22.62%	36.60%	-103.37%	3,543.80%	6.47%	41.23%	-70.25%	383.27%
Net Income Q/Q Growth	-49.94%	52.41%	33.48%	-30.59%	31.10%	-103.26%	3,914.81%	2.43%	32.28%	-67.30%	354.48%
EPS Q/Q Growth	-50.00%	53.33%	32.92%	-30.37%	30.87%	-103.08%	4,133.33%	2.48%	32.26%	-67.38%	356.07%
Operating Cash Flow Q/Q Growth	-53.10%	87.33%	-24.99%	4.08%	-63.49%	246.49%	-114.25%	473.84%	25.75%	153.16%	-33.35%
Free Cash Flow Firm Q/Q Growth	-94.17%	52.40%	-7.36%	-24.97%	-46.08%	-117.08%	-11.82%	-18.82%	-19.49%	-29.04%	40.53%
Invested Capital Q/Q Growth	1.72%	-1.40%	10.51%	3.67%	6.96%	3.46%	18.97%	6.90%	12.03%	3.38%	10.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	77.95%	77.25%	78.80%	76.63%	78.26%	80.42%	80.88%	80.91%	80.80%	81.02%	82.24%
EBITDA Margin	22.19%	27.78%	33.85%	27.18%	29.54%	8.82%	30.97%	33.49%	34.78%	17.97%	40.82%
Operating Margin	18.65%	24.15%	25.15%	21.47%	25.57%	4.74%	25.53%	28.62%	32.87%	13.34%	38.05%
EBIT Margin	16.81%	22.55%	28.71%	21.98%	25.13%	4.50%	26.82%	28.92%	31.12%	13.89%	37.23%
Profit (Net Income) Margin	14.68%	20.91%	26.54%	19.32%	21.21%	-0.60%	23.41%	25.58%	26.25%	8.48%	32.59%
Tax Burden Percent	87.31%	92.73%	92.43%	87.92%	84.41%	-13.44%	87.28%	88.44%	84.36%	61.09%	87.52%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	12.69%	7.27%	7.57%	12.08%	15.59%	113.44%	12.72%	11.56%	15.64%	38.91%	12.48%
Return on Invested Capital (ROIC)	24.76%	33.93%	31.06%	23.52%	27.44%	-0.87%	28.06%	31.80%	34.33%	10.25%	40.59%
ROIC Less NNEP Spread (ROIC-NNEP)	23.86%	32.92%	33.17%	23.79%	27.20%	-0.84%	28.71%	31.94%	33.45%	10.44%	40.20%
Return on Net Nonoperating Assets (RNNOA)	35.67%	37.21%	37.93%	27.13%	36.58%	-1.01%	43.19%	43.58%	51.40%	16.04%	77.98%
Return on Equity (ROE)	60.43%	71.14%	68.99%	50.66%	64.01%	-1.87%	71.25%	75.37%	85.73%	26.29%	118.57%
Cash Return on Invested Capital (CROIC)	15.40%	19.51%	16.04%	11.45%	8.55%	-3.21%	-11.80%	-12.62%	-14.77%	-12.53%	-1.55%
Operating Return on Assets (OROA)	10.30%	13.79%	16.67%	12.16%	14.56%	2.74%	16.13%	17.75%	19.12%	8.50%	23.50%
Return on Assets (ROA)	9.00%	12.79%	15.41%	10.69%	12.29%	-0.37%	14.08%	15.70%	16.13%	5.19%	20.57%
Return on Common Equity (ROCE)	59.12%	69.99%	67.95%	50.08%	63.37%	-1.86%	70.54%	74.78%	85.18%	26.12%	117.77%
Return on Equity Simple (ROE_SIMPLE)	66.61%	59.91%	0.00%	50.82%	58.73%	44.46%	0.00%	47.91%	54.14%	58.78%	0.00%
Net Operating Profit after Tax (NOPAT)	1,057	1,555	1,697	1,314	1,794	-61	2,084	2,219	3,134	932	4,506
NOPAT Margin	16.29%	22.40%	23.25%	18.87%	21.59%	-0.64%	22.28%	25.31%	27.72%	8.15%	33.30%
Net Nonoperating Expense Percent (NNEP)	0.91%	1.01%	-2.11%	-0.27%	0.23%	-0.02%	-0.65%	-0.15%	0.88%	-0.19%	0.40%
Return On Investment Capital (ROIC_SIMPLE)	-	-	6.28%	-	-	-	5.77%	-	-	-	9.40%
Cost of Revenue to Revenue	22.05%	22.75%	21.20%	23.37%	21.74%	19.58%	19.12%	19.09%	19.20%	18.98%	17.76%
SG&A Expenses to Revenue	25.05%	23.25%	22.50%	25.13%	23.16%	18.99%	20.58%	22.27%	18.73%	18.36%	17.92%
R&D to Revenue	34.25%	26.87%	30.62%	30.03%	29.52%	56.68%	34.06%	30.03%	25.35%	48.61%	23.73%
Operating Expenses to Revenue	59.30%	53.10%	53.65%	55.16%	52.68%	75.68%	55.36%	52.30%	47.93%	67.68%	44.19%
Earnings before Interest and Taxes (EBIT)	1,091	1,566	2,096	1,530	2,089	427	2,509	2,536	3,517	1,588	5,039
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,440	1,928	2,471	1,892	2,455	838	2,897	2,937	3,932	2,055	5,524
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	33.56	28.52	30.52	27.41	37.93	42.79	48.48	54.71	60.28	56.30	49.09
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	10,155.10	5,155.08	1,358.09	0.00	631.25	706.14	414.50	308.90
Price to Revenue (P/Rev)	9.86	9.82	11.39	11.08	14.22	14.97	15.30	19.51	21.00	19.62	15.47
Price to Earnings (P/E)	50.38	47.60	52.05	53.93	64.58	96.24	99.65	114.19	111.34	95.79	65.79
Dividend Yield	1.15%	1.19%	1.09%	1.20%	0.91%	0.82%	0.78%	0.60%	0.54%	0.57%	0.67%
Earnings Yield	1.98%	2.10%	1.92%	1.85%	1.55%	1.04%	1.00%	0.88%	0.90%	1.04%	1.52%
Enterprise Value to Invested Capital (EV/IC)	14.19	14.36	14.67	13.44	17.04	18.83	17.31	21.58	22.43	21.34	16.98
Enterprise Value to Revenue (EV/Rev)	10.26	10.19	11.78	11.53	14.67	15.44	15.87	20.08	21.59	20.22	16.07
Enterprise Value to EBITDA (EV/EBITDA)	38.04	36.58	40.37	41.29	49.50	64.67	67.01	79.06	79.24	69.90	50.10
Enterprise Value to EBIT (EV/EBIT)	47.89	45.47	49.41	50.82	59.47	80.62	82.62	95.43	93.47	81.40	57.08
Enterprise Value to NOPAT (EV/NOPAT)	44.05	44.86	51.42	56.73	68.02	103.22	104.89	118.94	113.52	98.84	67.19
Enterprise Value to Operating Cash Flow (EV/OCF)	39.26	36.39	44.33	47.00	69.36	79.67	127.72	196.32	186.31	136.97	82.09
Enterprise Value to Free Cash Flow (EV/FCFF)	101.32	79.10	98.17	125.50	218.06	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.94	1.56	1.51	1.67	1.69	1.78	2.32	2.03	2.12	2.17	2.36
Long-Term Debt to Equity	1.70	1.39	1.37	1.67	1.63	1.59	1.69	1.90	1.74	2.03	2.00
Financial Leverage	1.50	1.13	1.14	1.14	1.34	1.19	1.50	1.36	1.54	1.54	1.94
Leverage Ratio	6.19	5.28	4.93	4.82	5.14	4.91	5.25	4.84	5.11	5.21	5.68
Compound Leverage Factor	6.19	5.28	4.93	4.82	5.14	4.91	5.25	4.84	5.11	5.21	5.68
Debt to Total Capital	66.01%	60.98%	60.11%	62.57%	62.80%	64.08%	69.90%	67.02%	67.94%	68.48%	70.22%
Short-Term Debt to Total Capital	8.33%	6.70%	5.56%	0.01%	2.21%	7.13%	19.13%	4.22%	12.14%	4.56%	10.68%
Long-Term Debt to Total Capital	57.68%	54.29%	54.56%	62.56%	60.59%	56.94%	50.77%	62.80%	55.80%	63.92%	59.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.45%	0.37%	0.46%	0.35%	0.29%	0.28%	0.25%	0.22%	0.17%	0.18%	0.17%
Common Equity to Total Capital	33.54%	38.65%	39.42%	37.08%	36.92%	35.65%	29.85%	32.76%	31.89%	31.34%	29.62%
Debt to EBITDA	2.14	1.95	1.95	2.44	2.15	2.63	3.12	2.87	2.72	2.63	2.33
Net Debt to EBITDA	1.47	1.30	1.34	1.61	1.51	1.96	2.38	2.25	2.14	2.06	1.87
Long-Term Debt to EBITDA	1.87	1.74	1.77	2.44	2.08	2.34	2.27	2.69	2.24	2.46	1.97
Debt to NOPAT	2.48	2.39	2.48	3.36	2.96	4.20	4.89	4.32	3.90	3.72	3.12
Net Debt to NOPAT	1.70	1.59	1.70	2.21	2.08	3.12	3.73	3.39	3.06	2.92	2.51
Long-Term Debt to NOPAT	2.17	2.13	2.25	3.36	2.85	3.74	3.55	4.05	3.21	3.47	2.65
Altman Z-Score	5.47	5.69	6.06	5.40	6.75	7.03	6.75	9.33	9.43	8.82	7.58
Noncontrolling Interest Sharing Ratio	2.18%	1.62%	1.51%	1.14%	1.01%	0.85%	1.00%	0.78%	0.64%	0.65%	0.68%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.10	1.13	1.05	1.30	1.13	1.05	0.94	1.35	1.11	1.27	1.15
Quick Ratio	0.67	0.71	0.63	0.79	0.63	0.58	0.52	0.68	0.61	0.63	0.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,771	-1,319	-1,416	-1,770	-2,586	-5,613	-6,277	-7,458	-8,911	-11,499	-6,839
Operating Cash Flow to CapEx	318.95%	359.15%	332.08%	258.88%	85.60%	225.65%	-29.13%	118.22%	119.71%	274.81%	165.36%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.61	0.61	0.58	0.55	0.58	0.61	0.60	0.61	0.61	0.61	0.63
Accounts Receivable Turnover	3.99	3.81	3.42	3.29	3.50	3.43	3.43	3.78	3.50	3.65	3.66
Inventory Turnover	1.81	1.84	1.62	1.47	1.51	1.57	1.40	1.34	1.33	1.26	1.26
Fixed Asset Turnover	3.23	3.21	2.98	2.82	2.89	3.03	2.96	2.97	2.98	2.92	3.00
Accounts Payable Turnover	4.29	4.39	3.68	3.59	3.17	3.32	3.13	3.18	2.78	2.93	2.89
Days Sales Outstanding (DSO)	91.50	95.81	106.69	110.90	104.15	106.34	106.40	96.68	104.33	100.11	99.72
Days Inventory Outstanding (DIO)	201.86	198.02	225.60	249.00	241.93	232.92	259.81	272.55	274.79	289.13	289.67
Days Payable Outstanding (DPO)	85.12	83.17	99.13	101.79	114.97	109.84	116.72	114.93	131.52	124.47	126.33
Cash Conversion Cycle (CCC)	208.24	210.66	233.17	258.12	231.11	229.41	249.50	254.30	247.59	264.77	263.06
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	21,031	20,738	22,918	23,759	25,411	26,290	31,278	33,436	37,456	38,722	42,623
Invested Capital Turnover	1.52	1.51	1.34	1.25	1.27	1.36	1.26	1.26	1.24	1.26	1.22
Increase / (Decrease) in Invested Capital	3,828	2,874	3,114	3,084	4,380	5,553	8,361	9,677	12,045	12,432	11,345
Enterprise Value (EV)	298,351	297,855	336,279	319,252	432,955	495,154	541,565	721,568	840,226	826,258	723,817
Market Capitalization	286,747	287,188	325,028	306,684	419,623	480,084	522,228	700,944	817,502	801,776	696,733
Book Value per Share	$8.99	$10.60	$11.21	$11.78	$11.66	$11.82	$11.35	$14.22	$14.27	$14.98	$14.95
Tangible Book Value per Share	($2.99)	($1.00)	($0.66)	$0.03	$0.09	$0.37	($1.13)	$1.23	$1.22	$2.04	$2.38
Total Capital	25,473	26,054	27,014	30,179	29,969	31,476	36,089	39,109	42,528	45,440	47,916
Total Debt	16,814	15,888	16,239	18,884	18,820	20,168	25,225	26,211	28,892	31,120	33,644
Total Long-Term Debt	14,692	14,144	14,738	18,881	18,158	17,924	18,321	24,560	23,730	29,045	28,527
Net Debt	11,490	10,572	11,125	12,464	13,246	14,983	19,245	20,538	22,650	24,401	27,005
Capital Expenditures (CapEx)	371	617	501	669	738	970	1,071	986	1,225	1,351	1,496
Debt-free, Cash-free Net Working Capital (DFCFNWC)	880	990	186	1,135	249	760	2,411	5,656	4,881	5,297	6,057
Debt-free Net Working Capital (DFNWC)	3,616	3,732	2,397	4,805	3,078	3,254	5,338	8,242	8,245	8,815	9,480
Net Working Capital (NWC)	1,495	1,987	896	4,801	2,417	1,009	-1,566	6,591	3,083	6,741	4,363
Net Nonoperating Expense (NNE)	104	103	-240	-31	31	-3.12	-106	-24	167	-38	96
Net Nonoperating Obligations (NNO)	12,372	10,572	12,142	12,464	14,262	14,983	20,415	20,538	23,821	24,401	28,351
Total Depreciation and Amortization (D&A)	349	363	375	362	366	411	388	401	414	467	485
Debt-free, Cash-free Net Working Capital to Revenue	3.03%	3.38%	0.65%	4.10%	0.84%	2.37%	7.06%	15.74%	12.54%	12.96%	13.45%
Debt-free Net Working Capital to Revenue	12.44%	12.76%	8.40%	17.35%	10.43%	10.14%	15.64%	22.94%	21.18%	21.57%	21.05%
Net Working Capital to Revenue	5.14%	6.80%	3.14%	17.34%	8.19%	3.15%	-4.59%	18.34%	7.92%	16.50%	9.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.06	$1.61	$2.15	$1.49	$1.96	($0.06)	$2.43	$2.49	$3.29	$1.08	$4.90
Adjusted Weighted Average Basic Shares Outstanding	900.30M	900.70M	901.74M	901M	899.70M	899.80M	900.18M	900.80M	900.90M	901M	900.61M
Adjusted Diluted Earnings per Share	$1.05	$1.61	$2.14	$1.49	$1.95	($0.06)	$2.42	$2.48	$3.28	$1.07	$4.88
Adjusted Weighted Average Diluted Shares Outstanding	902.90M	903.80M	904.62M	903.30M	902.70M	899.80M	903.28M	903.80M	904.20M	905M	904.06M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	950.17M	950.18M	950.30M	949.27M	949.30M	949.31M	950.16M	950.41M	950.43M	949.32M	948.17M
Normalized Net Operating Profit after Tax (NOPAT)	1,057	1,746	1,697	1,314	1,794	315	2,084	2,219	3,501	982	4,506
Normalized NOPAT Margin	16.29%	25.15%	23.25%	18.87%	21.59%	3.32%	22.28%	25.31%	30.97%	8.59%	33.30%
Pre Tax Income Margin	16.81%	22.55%	28.71%	21.98%	25.13%	4.50%	26.82%	28.92%	31.12%	13.89%	37.23%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	58.21%	56.76%	56.62%	64.49%	58.51%	78.90%	77.65%	68.77%	59.60%	54.12%	44.20%
Augmented Payout Ratio	97.74%	94.06%	80.64%	77.68%	70.05%	93.93%	91.96%	68.77%	59.60%	59.45%	67.80%

Frequently Asked Questions About Eli Lilly and Company's Financials

When does Eli Lilly and Company's fiscal year end?

According to the most recent income statement we have on file, Eli Lilly and Company's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Eli Lilly and Company's net income changed over the last 9 years?

Eli Lilly and Company's net income appears to be on an upward trend, with a most recent value of $10.59 billion in 2024, rising from $2.41 billion in 2015. The previous period was $5.24 billion in 2023.

What is Eli Lilly and Company's operating income?

Eli Lilly and Company's total operating income in 2024 was $12.90 billion, based on the following breakdown:

Total Gross Profit: $36.62 billion
Total Operating Expenses: $23.73 billion

How has Eli Lilly and Company revenue changed over the last 9 years?

Over the last 9 years, Eli Lilly and Company's total revenue changed from $19.96 billion in 2015 to $45.04 billion in 2024, a change of 125.7%.

How much debt does Eli Lilly and Company have?

Eli Lilly and Company's total liabilities were at $64.44 billion at the end of 2024, a 21.3% increase from 2023, and a 207.2% increase since 2015.

How much cash does Eli Lilly and Company have?

In the past 9 years, Eli Lilly and Company's cash and equivalents has ranged from $2.07 billion in 2022 to $7.32 billion in 2018, and is currently $3.27 billion as of their latest financial filing in 2024.

How has Eli Lilly and Company's book value per share changed over the last 9 years?

Over the last 9 years, Eli Lilly and Company's book value per share changed from 13.15 in 2015 to 14.95 in 2024, a change of 13.7%.

Related Companies

This page (NYSE:LLY) was last updated on 4/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Financials

Frequently Asked Questions About Eli Lilly and Company's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eli Lilly and Company (LLY) Financials

Annual Income Statements for Eli Lilly and Company

Quarterly Income Statements for Eli Lilly and Company

Annual Cash Flow Statements for Eli Lilly and Company

Quarterly Cash Flow Statements for Eli Lilly and Company

Annual Balance Sheets for Eli Lilly and Company

Quarterly Balance Sheets for Eli Lilly and Company

Annual Metrics and Ratios for Eli Lilly and Company

Quarterly Metrics and Ratios for Eli Lilly and Company

Frequently Asked Questions About Eli Lilly and Company's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools